Celogos and SMS KK agree myoblast transplantation deal
French biotechnology firm Celogos and Japan's Stem Cell Sciences KK, a joint venture established by Australia's Stem Cell Sciences and Japanese firm Sosei, have agreed a licensing deal which covers use of the former's myoblast cell implantation expertise in the development of a treatment for urinary incontinence. Financial terms of the accord, which covers the commercialization of such products in Japan, were not provided.
Celogos explained that the alliance is based on its Rational Cell Design platform that enables the development, optimization, production and transplantation of novel cells. The Parisian firm went on to say that the RCD technology had allowed it to create a protocol for myoblast implantation as a treatment for UTI patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze